Celltrion announced that its consolidated operating profit for the third quarter of this year reached 525.3 billion won, a 74.3% increase compared to the same period last year.
Revenue was reported at 1.5755 trillion won, marking a 53.1% rise from the previous year. However, net profit fell to 78.4 billion won, a decrease of 76.4%.
The finalized results reflect an increase of 75.5 billion won in revenue and 15.3 billion won in operating profit compared to the preliminary figures released on October 12. Despite accounting for research and development (R&D) expenses for new drugs and next-generation products, the company achieved its highest operating profit to date.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.